Summary by Moomoo AI
NeuroSense Therapeutics, a clinical-stage biotech company, reported a net loss of $10.21M for fiscal year 2024, slightly higher than the $10.10M loss in 2023. The company ended the year with a cash position of $3.4M, while R&D expenses decreased to $5.70M from $7.27M in the previous year. G&A expenses also reduced to $4.20M from $4.78M, reflecting cost management efforts.The company's financial position remains challenging with no revenue generation to date and significant operating losses. Share-based compensation decreased to $0.56M from $1.54M in 2023, with 1,069,128 outstanding options and 200,000 RSUs as of December 31, 2024. The company maintains substantial tax loss carryforwards of $24.73M for Israeli tax purposes.In early 2025, NeuroSense raised $509,000 through the sale of ordinary shares and approved new equity grants to employees and consultants. However, the company faces ongoing concerns about funding adequacy, particularly for Phase 3 trials, and continues to rely on external financing to sustain operations and advance its neurodegenerative disease treatment pipeline.
Comment(0)
Reason For Report